文献速递白血病造血干细胞移植与细胞治疗

地西他滨联合白消安-环磷酰胺预处理降低KMT2A重排白血病移植后复发:一项3期随机试验

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.
PubMed 文献 · Lancet Haematol · 2026-01-01

该研究为在中国8个移植中心开展的开放标签、多中心、随机3期试验,纳入130例14-65岁KMT2A重排白血病患者,比较地西他滨联合白消安-环磷酰胺(DAC-BuCy)与白消安-环磷酰胺(BuCy)清髓预处理。

要点

  • DAC-BuCy方案较BuCy方案降低2年累积复发率(12% vs 29%)。
  • 两组3-5级不良事件发生率相近,安全性可接受。
  • DAC-BuCy可作为成人KMT2A重排白血病移植前预处理的选择。

核心结论

  • 在成人KMT2A重排白血病患者中,BuCy预处理基础上加用地西他滨可降低移植后复发风险,且安全性可接受。

研究设计与样本

  • 开放标签、多中心、随机3期试验,在中国8个移植中心开展,共随机130例患者(DAC-BuCy组65例,BuCy组65例)。

主要发现

  • 最常见的3-5级不良事件为感染或寄生虫病(DAC-BuCy组27例[42%],BuCy组25例[38%])、急性移植物抗宿主病(23例[35%] vs 22例[34%])和胃肠道疾病(14例[22%] vs 15例[23%])。
  • DAC-BuCy组4例(6%)和BuCy组5例(8%)患者死于不良事件,其中2例与方案相关毒性有关。

关键数值与推荐

  • BuCy方案:白消安和环磷酰胺的剂量与持续时间同DAC-BuCy方案。

临床怎么用

  • 对于成人KMT2A重排白血病患者,在异基因造血干细胞移植前可考虑采用DAC-BuCy清髓预处理以降低复发风险。

局限性

  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An unmet need persists for optimal myeloablative conditioning before allogeneic haematopoietic stem cell transplantation (HSCT) in adult KMT2A‑rearranged leukaemia. We investigated whether decitabine plus busulfan-cyclophosphamide (DAC-BuCy) conditioning reduced the risk of relapse compared with busulfan-cyclophosphamide (BuCy) conditioning. METHODS: In this open-label, randomised, phase 3 trial at eight transplantation centres in China, eligible patients were aged 14-65 years, had morphologically confirmed KMT2A-rearranged leukaemia, and had an Eastern Cooperative Oncology Group performance status of 0-2. Patients were randomly assigned (1:1) before HSCT to DAC-BuCy (intravenous decitabine 20 mg/m2 once a day on days -14 to -10, intravenous busulfan 3·2 mg/kg once a day on days -7 to -4, and intravenous cyclophosphamide 60 mg/kg once a day on days -3 to -2) or BuCy (same dose and duration of busulfan and cyclophosphamide). Randomisation was done with permuted blocks (block size four) with no stratification and was implemented through an independent, interactive, web-based response system. The primary endpoint was 2-year cumulative incidence of relapse in the intention-to-treat population. Safety was assessed in all patients who received treatment. This trial is registered with ClinicalTrials.gov (NCT03596892) and is complete. FINDINGS: Between May 1, 2019, and Jan 31, 2023, 130 patients were randomised to receive a DAC-BuCy (n=65; 34 [52%] female and 31 [48%] male) or BuCy (n=65; 29 [45%] female and 36 [55%] male) regimen. Median follow-up was 34·7 months (IQR 30·2-52·5). 2-year cumulative incidence of relapse was 12% (95% CI 6-22) in the DAC-BuCy group and 29% (19-41) in the BuCy group (hazard ratio 0·41 [0·20-0·87]; p=0·017). The most common grade 3-5 adverse events were infections or infestations (DAC-BuCy group 27 [42%] and BuCy group 25 [38%]), acute graft-versus-host disease (DAC-BuCy group 23 [35%] and BuCy group 22 [34%]), and gastrointestinal disorders (DAC-BuCy group 14 [22%] and BuCy group 15 [23%]). Four (6%) patients in the DAC-BuCy group and five (8%) patients in the BuCy group died from adverse events, of which two were due to regimen-related toxicities: one nervous system disorder in the DAC-BuCy group and one cardiac disorder in the BuCy group. INTERPRETATION: The addition of decitabine to BuCy conditioning reduced the risk of relapse with an acceptable safety profile in adult patients with KMT2A‑rearranged leukaemia and could be a suitable therapeutic option for this population. FUNDING: The National Natural Science Foundation of China, the National Key Research and Development Program of China, the Science and Technology Program of Guangdong Province, the Non-communicable Chronic Diseases-National Science and Technology Major Project, the Natural Science Foundation of Guangdong Province, the Science and Technology Planning Project of Guangzhou, and the Outstanding Youth Cultivation Program of Nanfang Hospital, Southern Medical University. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Hu, Fan, Dai, et al. Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial. Lancet Haematol. 2026. PMID: 42956759. doi:10.1016/S2352-3026(26)00250-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。